CTLA4 Antikörper (PE-Cy7)

Produktnummer ABIN2659106

Der PE-Cy7-konjugierte Hamster Monoklonal anti-CTLA4 Antikörper (Klon UC10-4B9) (ABIN2659106) detektiert spezifisch CTLA4 in FACS. Dieser Antikörper reagiert spezifisch mit Proben aus Maus.

Kurzübersicht für CTLA4 Antikörper (PE-Cy7) (ABIN2659106)

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Reaktivität: Maus

Wirt: Hamster

Klonalität: Monoklonal

Konjugat: Dieser CTLA4 Antikörper ist konjugiert mit PE-Cy7

Applikation: Flow Cytometry (FACS)

Klon: UC10-4B9

Produktdetails anti-CTLA4 Antikörper (PE-Cy7)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu CTLA4

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Andere Bezeichnung: CD152

Hintergrund: CD152, also known as CTLA-4 or Ly-56, is a 33 kD member of the immunoglobulin superfamily. It is expressed on activated T and B lymphocytes. CD152 is similar to CD28 in amino acid sequence, structure, and genomic organization and these two receptors share common B7 family counter-receptors (B7-1, B7-2). Whereas CD28 delivers a costimulatory signal in T cell activation, CTLA-4 negatively regulates cell-mediated immune responses. CD152 is thought to play a role in the induction and maintenance of immunological tolerance as well as the development of protective immunity and thymocyte regulation.

Pathways: Cancer Immune Checkpoints